THE EXPERIENCE OF THE USAGE OF BLOCKER OF AT1-ANGIOTENZINE RECEPTOR APROVEL ON HYPERTENSIVE PATIENTS

The aim of the research was to study clinical effects and acceptability of a new AT1-recepotor blocker ? irbesartan (aprovel, Sanofi/BMS). 30 patients with soft and moderate arterial hypertension were examined, the average age of the examined persons is 52,6?6,1 years old, duration of disease - 9,7 years. The prescribed dose of aprovel was 150 mg per day for 12 weeks, the dose was corrected after 4 weeks of therapy. All the patients passed 24 hours' blood pressure monitoring ( device of MEDITEX, ABPM, Hungary) before the start of treat-ment and on 4, 8, 12after it. The following indices were analyzed: middle systolic and diastolic blood pressure (24-hours, day, night), variability of blood pressure, hypertension time and square indices. This study showed the efficacy of aprovel monotherapy (the dose made up 150 ? 300 mg per day). The preparation causes a stable hypotensive effect, decreasing systolic and diastolic blood pressure after 6 ? 8 week of treat- ment. The hypotensive effect of aprovel depends on the dose of the preparation. Aprovel does not influence nor-mal circadian low daily blood pressure rhythm and corrects pathologicone.